Signablok, Inc.
Worcester, MA Doing business as Signablok Inc.
- UEI
- JM5UN38YM1H7
- CAGE
- 5Z7P9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 61 Frank St #36, Worcester, MA 01604, USA
- Website
- signablok.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome - project summary/abstract… | National Institute of Allergy and Infectious Diseases | $155,857 | |
| Trem-1 therapy for the treatment of empyema - project summary/abstract the incidence of empyema is increasing and… | National Heart Lung and Blood Institute | $457,954 | |
| First-in-class trem-1 inhibitors for neovascular retinal diseases - project summary/abstract retinal… | National Eye Institute | $2,217,236 | |
| New mechanism-based trem-1 therapy for acute respiratory distress syndrome - project summary/abstract every year,… | National Heart Lung and Blood Institute | $272,741 | |
| Trem-1 inhibitor for the treatment of scleroderma | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $249,601 |
About Signablok, Inc.
Signablok, Inc. is a corporate entity registered in SAM.gov since April 22, 2010, with its primary address located in Worcester, Massachusetts. The company appears to be a biotechnology research organization focused on developing innovative medical therapies, specifically targeting inflammation and molecular pathways related to various medical conditions. While limited publicly available information exists about the company's full operational scope, its federal grant award history demonstrates a clear specialization in developing novel therapeutic peptide-based interventions that inhibit the TREM-1 receptor to mitigate inflammatory responses across multiple medical domains.
The company has been awarded multiple federal grants from prestigious agencies like the National Institutes of Health, National Heart Lung and Blood Institute, and National Eye Institute, totaling approximately $613,811 in project grant funding between 2023 and 2026. These grants focus on developing first-in-class TREM-1 inhibitor therapies for critical medical conditions, including acute radiation syndrome, empyema, neovascular retinal diseases, and acute respiratory distress syndrome (ARDS). Signablok's research consistently centers on creating ligand-independent TREM-1 inhibitory peptides, particularly sequences named GF9 and GA31, which can be formulated into macrophage-specific lipopeptide complexes to improve therapeutic targeting and efficacy. The company's research aims to address significant medical challenges with mortality rates ranging from 25-45% in conditions like ARDS, retinopathy, and radiation exposure, presenting innovative approaches to suppressing inflammatory responses and potentially improving patient outcomes across multiple critical medical domains.
Quick answers
What is Signablok, Inc.'s UEI?
Signablok, Inc.'s Unique Entity ID (UEI) in SAM.gov is JM5UN38YM1H7.
What is Signablok, Inc.'s CAGE code?
Signablok, Inc.'s CAGE code is 5Z7P9.
What is Signablok, Inc.'s primary NAICS code?
Signablok, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Signablok, Inc. located?
Signablok, Inc.'s physical address in SAM.gov is 61 Frank St #36, Worcester, MA 01604, USA.
Is Signablok, Inc. registered in SAM.gov?
Yes. Signablok, Inc.'s SAM.gov registration is active through December 8, 2026.
What is Signablok, Inc.'s most recent federal award?
Signablok, Inc.'s most recent federal grant award is Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome - project summary/abstract… (R21AI193495), from National Institute of Allergy and Infectious Diseases, on September 19, 2025.
On GovTribe
See Signablok, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors